Literature DB >> 28453898

Electrophysiological effects of anthracyclines in adult survivors of pediatric malignancy.

Timothy M Markman1, Kathryn Ruble2,3, David Loeb2,3, Allen Chen2,3, Yiyi Zhang4, Gary S Beasley2,5, W Reid Thompson2,5, Saman Nazarian1,4,6,7.   

Abstract

BACKGROUND: Anthracycline use is limited by cardiotoxicity, including arrhythmias and left ventricular (LV) dysfunction. We aim to characterize the association between electrophysiological changes and LV dysfunction.
METHODS: A retrospective chart review was conducted, including all 147 pediatric cancer survivors at our institution over 18 years of age and treated with an anthracycline. One hundred thirty-four patients who had at least one electrocardiogram (ECG) and echocardiogram were analyzed. The association between dysfunction and baseline characteristics, treatment history, and electrocardigraphic parameters were analyzed using multivariable logistic regression. Additionally, a longitudinal generalized estimating equation (GEE) model was used to examine the temporal association between repeated measure corrected QT (QTc) intervals and subsequent LV function.
RESULTS: In our population, 24% of patients had LV dysfunction. The initial posttreatment QTc interval was longer in patients with LV dysfunction (438 ± 35 vs. 420 ± 20 msec, P = 0.002). In logistic regression analysis, QTc interval (P < 0.001) and cumulative radiation dose (P = 0.027) were associated with LV dysfunction. On ECGs performed prior to evidence of LV dysfunction, the QTc was longer than on ECGs preceding a normal echocardiogram (451 ± 32 msec vs. 423 ± 25 msec, P < 0.001). Mean time from QTc ≥ 450 msec to evidence of LV dysfunction was 1.8 ± 2.9 years. In the longitudinal GEE model, QTc prolongation was associated with subsequent decreased fractional shortening.
CONCLUSIONS: Among adult survivors of pediatric cancer treated with anthracyclines, prolongation of the QTc interval was associated with subsequent LV dysfunction.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  QTc interval; anthracycline; arrhythmia; cardiotoxicity after chemotherapy

Mesh:

Substances:

Year:  2017        PMID: 28453898     DOI: 10.1002/pbc.26556

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

Review 1.  Cardio-oncology: management of cardiovascular toxicity.

Authors:  Timothy M Markman; Maurie Markman
Journal:  F1000Res       Date:  2019-01-30

Review 2.  Cardio-Oncology: mechanisms of cardiovascular toxicity.

Authors:  Timothy M Markman; Maurie Markman
Journal:  F1000Res       Date:  2018-01-25

3.  Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer.

Authors:  Pedro Veronese; Denise Tessariol Hachul; Mauricio Ibrahim Scanavacca; Ludhmila Abrahão Hajjar; Tan Chen Wu; Luciana Sacilotto; Carolina Veronese; Francisco Carlos da Costa Darrieux
Journal:  PLoS One       Date:  2018-05-03       Impact factor: 3.240

4.  Electrocardiograms for cardiomyopathy risk stratification in children with anthracycline exposure.

Authors:  Lajja Desai; Lauren Balmert; Jennifer Reichek; Amanda Hauck; Katheryn Gambetta; Gregory Webster
Journal:  Cardiooncology       Date:  2019-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.